KNSA
Price
$40.29
Change
-$0.29 (-0.71%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
3.08B
110 days until earnings call
Intraday BUY SELL Signals
MDXXF
Price
$0.08
Change
-$0.01 (-11.11%)
Updated
Nov 11 closing price
Capitalization
8.52M
Intraday BUY SELL Signals
Interact to see
Advertisement

KNSA vs MDXXF

Header iconKNSA vs MDXXF Comparison
Open Charts KNSA vs MDXXFBanner chart's image
Kiniksa Pharmaceuticals International
Price$40.29
Change-$0.29 (-0.71%)
Volume$7.17K
Capitalization3.08B
PharmAla Biotech Holdings
Price$0.08
Change-$0.01 (-11.11%)
Volume$16K
Capitalization8.52M
KNSA vs MDXXF Comparison Chart in %
KNSA
Daily Signal:
Gain/Loss:
MDXXF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
KNSA vs. MDXXF commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KNSA is a Buy and MDXXF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (KNSA: $40.58 vs. MDXXF: $0.08)
Brand notoriety: KNSA and MDXXF are both not notable
KNSA represents the Pharmaceuticals: Generic, while MDXXF is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: KNSA: 93% vs. MDXXF: 87%
Market capitalization -- KNSA: $3.05B vs. MDXXF: $9.3M
KNSA [@Pharmaceuticals: Generic] is valued at $3.05B. MDXXF’s [@Biotechnology] market capitalization is $9.3M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.14B. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KNSA’s FA Score shows that 0 FA rating(s) are green whileMDXXF’s FA Score has 0 green FA rating(s).

  • KNSA’s FA Score: 0 green, 5 red.
  • MDXXF’s FA Score: 0 green, 5 red.
According to our system of comparison, KNSA is a better buy in the long-term than MDXXF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KNSA’s TA Score shows that 4 TA indicator(s) are bullish while MDXXF’s TA Score has 2 bullish TA indicator(s).

  • KNSA’s TA Score: 4 bullish, 4 bearish.
  • MDXXF’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, KNSA is a better buy in the short-term than MDXXF.

Price Growth

KNSA (@Pharmaceuticals: Generic) experienced а +3.68% price change this week, while MDXXF (@Biotechnology) price change was -10.11% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.08%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +32.16%.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

KNSA is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KNSA($3.08B) has a higher market cap than MDXXF($8.52M). KNSA YTD gains are higher at: 105.157 vs. MDXXF (-53.890). KNSA has higher annual earnings (EBITDA): 5.98M vs. MDXXF (-1.86M). KNSA has more cash in the bank: 308M vs. MDXXF (1.25M). KNSA has higher revenues than MDXXF: KNSA (529M) vs MDXXF (421K).
KNSAMDXXFKNSA / MDXXF
Capitalization3.08B8.52M36,098%
EBITDA5.98M-1.86M-322%
Gain YTD105.157-53.890-195%
P/E Ratio90.20N/A-
Revenue529M421K125,653%
Total Cash308M1.25M24,739%
Total Debt9.77MN/A-
FUNDAMENTALS RATINGS
KNSA: Fundamental Ratings
KNSA
OUTLOOK RATING
1..100
72
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
PROFIT vs RISK RATING
1..100
35
SMR RATING
1..100
90
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
KNSAMDXXF
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
N/A
Declines
ODDS (%)
Bearish Trend 7 days ago
77%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
KNSA
Daily Signal:
Gain/Loss:
MDXXF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DBI4.040.24
+6.32%
Designer Brands
CLSD3.830.03
+0.92%
Clearside Biomedical Inc
GWW944.97-0.64
-0.07%
WW Grainger
ATUS1.96-0.01
-0.51%
Altice USA
MDU21.18-0.15
-0.70%
MDU Resources Group

KNSA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KNSA has been loosely correlated with COYA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if KNSA jumps, then COYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KNSA
1D Price
Change %
KNSA100%
+0.02%
COYA - KNSA
42%
Loosely correlated
+1.33%
ABVC - KNSA
40%
Loosely correlated
+3.46%
JBIO - KNSA
37%
Loosely correlated
+2.04%
AMRN - KNSA
36%
Loosely correlated
+0.75%
CPRX - KNSA
36%
Loosely correlated
-1.39%
More

MDXXF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDXXF has been loosely correlated with NICXF. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXXF jumps, then NICXF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDXXF
1D Price
Change %
MDXXF100%
N/A
NICXF - MDXXF
46%
Loosely correlated
N/A
ABVC - MDXXF
25%
Poorly correlated
+3.46%
ZIVO - MDXXF
23%
Poorly correlated
N/A
KNSA - MDXXF
20%
Poorly correlated
+0.02%
VYGR - MDXXF
20%
Poorly correlated
-0.23%
More